🔗 Share this article

As the United States undertakes unprecedented changes to its immunization schedules, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by casting doubt on COVID-19 shots during the pandemic and has concentrated on potential fatalities following COVID-19 vaccination in her short time at the FDA.

Scheduled Changes to Childhood Immunization Program

Public health authorities were set to announce radical revisions to the childhood vaccination calendar earlier this month, bringing the US with Denmark’s immunization schedule, it is understood – a significant shift that would put the US at odds with much of the global community with no evidence for benefit. The planned update has been postponed until the coming year.

Instead of Vinay Prasad, Høeg is set to address the audience at the gathering. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this year.

Consolidating Power at the Regulatory Body

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad consolidate power at the agency – and it signals a greater focus upon dismantling already-approved immunizations at the FDA.

The new acting director has repeatedly called for ending specific childhood vaccine recommendations in the US in order to be more like Denmark, a country with nationalized medicine and a citizenry approximately the population of Wisconsin’s.

So far statements, she has continued to focus on vaccination policy – typically the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Expertise

Dr. Høeg has no apparent experience in pharmaceutical research, regulation or leadership, which has been customary for past leaders of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since March.

“She appears not to have the requisite experience” for running the CDER, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in leading a large organization. She lacks background in industry regulation.”

Former commissioners of the center would “grasp regulatory frameworks and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that previous people who headed CBER have had.”

CDER has an vast portfolio at the agency, she stated.

“Many people just focuses on the new drug program, but the generic drug division clears thousands of generic medications. There’s a biosimilars division, over-the-counter program and other areas, and every single one have to be supervised,” Dr. Woodcock noted. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a major administrative aspect to the job, which oversees over 5,000 employees. “It is a massive leadership role, if you execute it properly,” she concluded.

Official Statement and Controversial Programs

In response to questions about Dr. Høeg's fitness for the role and whether this appointment represents increased cooperation among regulatory chiefs on vaccines, a representative responded that the “inquiries stem from inaccurate premises”.

“Her resume aligns with the functions of her position,” the spokesperson said, noting the months Høeg spent counseling the FDA commissioner on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the agency head's controversial priority voucher program, a controversial expedited drug-approval program that reportedly concerned her predecessors. “By what process are these drugs being selected for this expedited pathway? Who makes the choices?” Dr. Howard said. “There is a lot of lack of transparency going on at the agency right now.”

Broadly speaking, he stated, “the agency looks to be trending towards more relaxed regulations of most medications, aside from shots.”

Documented History on Vaccines

Regarding vaccines, Høeg has a more established, if troubling, history, some experts observe. She released a analysis using unverified volunteer-provided data to estimate the incidence of myocarditis following Covid vaccination. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccinations are more dangerous than they are.

Among her “policy goals” for the new government featured revising rules for new vaccines and halting “optional” vaccines, she remarked following the vote on a podcast. At the FDA, Høeg has allegedly proposed excluding teenage boys from receiving Covid vaccinations.

“She is an complete dogmatist who commences with her beliefs and works backwards to retrofit the data in a extremely misleading, untruthful manner,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with fellow skeptics, {like|